Cardiovascular Medicine and Haematology articles for Mayo Clinic, United States of America (USA)

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 69

Article ‘Count’ for Cardiovascular Medicine and Haematology.

Journal Count Share
1 0.05
The ICE-AFIB trial: A multicenter prospective investigational device exemption (IDE) trial using cryosurgical ablation for atrial fibrillation during concomitant cardiac surgery 0.05
5 0.49
Mucus plugs in chronic obstructive pulmonary disease are heterogeneous in size and shape and occur in relatively large airways 0.11
Associations of High Attenuation Area-related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities. 0.03
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry Analysis. 0.05
Associations of Prepandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study 0.06
Metabolomic Evidence of Biological Overlap with HFpEF in a Subset of Pulmonary Arterial Hypertension. 0.24
1 0.06
Transfusion of Amustaline/Glutathione Pathogen-Reduced Red Blood Cells in Cardiac Surgery - A Randomized Phase III Clinical Trial 0.06
1 0.03
Incidence and Clinical Relevance of Echocardiographic Visualization of Occult Ventricular Fibrillation: A Multicenter Prospective Study of Patients Presenting to the Emergency Department After Out-of-Hospital Cardiac Arrest 0.03
2 0.11
Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease 0.06
Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis 0.05
3 0.27
Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma 0.10
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study 0.03
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab 0.13
1 0.10
Development of a standard definition of ‘no-option’ and ‘poor-option’ for revascularization in chronic limb-threatening ischemia 0.10
5 1.52
The Epidemiology of Cryptogenic Organizing Pneumonia 0.20
Efficacy of Anti-Inflammatory Therapies for Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and Network Meta-Analysis 0.11
Treatment patterns in incident pulmonary hypertension patients: real-world data from the Pulmonary Hypertension Association Registry 0.11
Initial Evaluation of the Pulmonary Hypertension Functional Classification Self-Report (PH-FC-SR) Measurement Properties: A Patient-Focused Measure 0.10
Inter-session Variability in Single-Breath Diffusing Capacity of Carbon Monoxide 1.00
3 0.46
Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension. 0.32
Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis. 0.03
Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study 0.11
8 1.62
Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry 0.01
Artificial intelligence–based quantification of breast arterial calcifications to predict cardiovascular morbidity and mortality 0.28
Arrhythmias in congenitally corrected transposition of the great arteries: an international study 0.05
Adults with Fontan circulation: prognostic value of exercise pulmonary vascular resistance index 0.63
Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification 0.06
Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial 0.06
Titin-related familial dilated cardiomyopathy: factors associated with disease onset 0.02
The Australian–New Zealand SCAD observational cohort study: major adverse cardiovascular events are associated with ticagrelor combined with aspirin, FMD, and history of stroke 0.50
2 0.07
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy 0.03
Real-World Outcomes of Transcatheter Tricuspid Valve Replacement 0.05
1 0.81
Functional Evaluation of TRPC6 Missense Variants in Cancer Patients via Molecular Docking Analysis Compared with Patch Clamp Electrophysiology 0.81
1 0.93
Myocardial Infarction Prior to TKA Is Associated with Increased Risk of Medical and Surgical Complications in a Time-Dependent Manner. 0.93
1 0.02
Cardiac radiotherapy-induced epigenetic memory underlies electrophysiologic and metabolic reprogramming 0.02
1 0.13
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma. 0.13
8 5.76
Ten-year outcomes of valve-replacing versus valve-sparing aortic root replacement in Marfan syndrome patients: An observational multicenter study 0.08
Does the Genotype of Hypertrophic Cardiomyopathy Impact the Outcomes of Septal Myectomy? 1.00
Changes in ejection fraction after coronary artery bypass grafting for ischemic cardiomyopathy: Impact on survival and determinants of improvement 1.00
Fontan pathway diameter in adults undergoing exercise catheterization: Association with hemodynamics, exercise capacity, and liver scores 0.59
Impact of Effective Orifice Area on Long-Term Survival in Bioprosthetic versus Mechanical Aortic Valves 1.00
Transcatheter Edge-to-Edge Repair versus Mitral Valve Surgery in Octogenarians: Comparative Analysis of Safety, Durability, and Survival 1.00
Risk Stratification of CABG Patients Using an Artificial Intelligence ECG-Derived Age 1.00
Impact of post-operative left bundle branch block on left ventricular remodeling following transapical beating-heart septal myectomy 0.08
9 3.71
Sotatercept in Pulmonary Arterial Hypertension 1.00
Echocardiographic Diastolic Function Grading in HFpEF Testing the Updated 2025 ASE Criteria 0.53
Proactive Management and Treatment of Aortic Stenosis: An International Expert Perspective 0.03
Tricuspid Regurgitation Across the Spectrum of Heart Failure With Preserved Ejection Fraction 1.00
Danicamtiv, a selective agonist of cardiac myosin, for dilated cardiomyopathy: A Phase 2 open-label trial 0.04
Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTOR 0.04
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy Exploratory Insights From the ODYSSEY-HCM Trial 0.05
Causes of Myocardial Infarction in Younger Patients Troponin-Elevation in Persons ≤65 Years Old in Olmsted County 1.00
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension Results of an International Multicenter Prospective Registry 0.03
3 0.09
CD39 polymorphism enables lung thrombosis in sickle cell disease 0.04
Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical models 0.03
Association between self-reported multimorbidity and longitudinal brain Aβ deposition in Alzheimer’s disease 0.02
2 0.09
Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial 0.08
Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study 0.01
1 0.20
Mouse radial spoke 3 is a metabolic and regulatory hub in cilia 0.20
2 0.81
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years 0.03
Artificial intelligence biomarker detects high-risk childhood asthma subgroup for respiratory infections and exacerbations 0.78
3 0.14
Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: a prospective, multicountry, single-arm trial 0.08
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials 0.03
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial 0.03
3 0.21
Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial 0.03
Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation 0.03
Medical Management and Revascularization for Asymptomatic Carotid Stenosis 0.16
2 0.57
Antifibrotic therapy and lung cancer risk in patients with idiopathic pulmonary fibrosis: a large retrospective propensity-weighted cohort study 0.50
Serum IgA isotypes are associated with percent emphysema, wall thickness and lung function decline 0.07

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.